Role of endothelin in preeclampsia and hypertension following antiangiogenesis treatment

Current Opinion in Nephrology and Hypertension

Volumn 25, Issue 2, 2016, Pages 94-99

  Saleh, Langeza ^a   Danser, Jan A H ^a   Van Den Meiracker, Anton H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

antiangiogenic treatment; endothelin 1; preeclampsia; soluble FMS like tyrosine kinase 1

Indexed keywords

ANGIOGENESIS INHIBITOR; ENDOTHELIN 1; ENDOTHELIN; ENDOTHELIN A RECEPTOR ANTAGONIST;

ANTIANGIOGENIC THERAPY; BLOOD PRESSURE; HUMAN; HYPERTENSION; NONHUMAN; PATHOPHYSIOLOGY; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; FEMALE; METABOLISM; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PRE-ECLAMPSIA; PREGNANCY;

ANGIOGENESIS INHIBITORS; ANIMALS; ENDOTHELIN A RECEPTOR ANTAGONISTS; ENDOTHELINS; FEMALE; HUMANS; HYPERTENSION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PRE-ECLAMPSIA; PREGNANCY;

EID: 84957428296     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000197     Document Type: Review

References (42)

1. Verdonk K, Saleh L, Lankhorst S, et al. Association studies suggest a key role for endothelin-1 in the pathogenesis of preeclampsia and the accompanying renin-angiotensin-aldosterone system suppression. Hypertension 2015; 65:1316-1323.
2. Rana S, Karumanchi SA, Lindheimer MD. Angiogenic factors in diagnosis, management, and research in preeclampsia. Hypertension 2014; 63:198-202.
3. Aggarwal PK, Chandel N, Jain V, et al. The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia. J Hum Hypertens 2012; 26:236-241.
4. Karakus S, Bozoklu Akkar O, Yildiz C, et al. Serum levels of ET-1, M30, and angiopoietins-1 and -2 in HELLP syndrome and preeclampsia compared to controls. Arch Gynecol Obstet 2015; 10:404-415.
5. Alexander BT, Kassab SE, Miller MT, et al. Reduced uterine perfusion pressure during pregnancy in the rat is associated with increases in arterial pressure and changes in renal nitric oxide. Hypertension 2001; 37:1191-1195.
6. Mazzuca MQ, Li W, Reslan OM, et al. Downregulation of microvascular endothelial type B endothelin receptor is a central vascular mechanism in hypertensive pregnancy. Hypertension 2014; 64:632-643.
7. Zhou J, Xiao D, Hu Y, et al. Gestational hypoxia induces preeclampsia-like symptoms via heightened endothelin-1 signaling in pregnant rats. Hypertension 2013; 62:599-607.
8. Herse F, Verlohren S, Wenzel K, et al. Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study. Hypertension 2009; 53:393-398.
9. Siddiqui AH, Irani RA, Blackwell SC, et al. Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with disease severity. Hypertension 2010; 55:386-393.
10. LaMarca B, Parrish MR, Wallace K. Agonistic autoantibodies to the angiotensin II type I receptor cause pathophysiologic characteristics of preeclampsia. Gend Med 2012; 9:139-146.
11. Lin YJ, Kwok CF, Juan CC, et al. Angiotensin II enhances endothelin-1-induced vasoconstriction through upregulating endothelin type A receptor. Biochem Biophys Res Commun 2014; 451:263-269.
12. Li F, Hagaman JR, Kim HS, et al. eNOS deficiency acts through endothelin to aggravate sFlt-1-induced preeclampsia-like phenotype. J Am Soc Nephrol 2012; 23:652-660.
13. Murphy SR, LaMarca BB, Cockrell K, et al. Role of endothelin in mediating soluble fms-like tyrosine kinase 1-induced hypertension in pregnant rats. Hypertension 2010; 55:394-398.
14. LaMarca BB, Bennett WA, Alexander BT, et al. Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of tumor necrosis factor-alpha. Hypertension 2005; 46:1022-1025.
15. Lankhorst S, Kappers MH, van Esch JH, et al. Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1. J Hypertens 2013; 31:444-454.
16. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358:1129-1136.
17. Izzedine H, Escudier B, Lhomme C, et al. Kidney diseases associated with antivascular endothelial growth factor (VEGF): an 8-year observational study at a single center. Medicine (Baltimore) 2014; 93:333-339.
18. Kappers MH, van Esch JH, Sluiter W, et al. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension 2010; 56:675-686.
19. de Jesus-Gonzalez N, Robinson E, Penchev R, et al. Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1. Am J Hypertens 2012; 25:1118-1123.
20. Kappers MH, Smedts FM, Horn T, et al. The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system. Hypertension 2011; 58:295-302.
21. Lankhorst S, Baelde HJ, Kappers MH, et al. Greater sensitivity of blood pressure than renal toxicity to tyrosine kinase receptor inhibition with sunitinib. Hypertension 2015; 66:543-549.
22. Kappers MH, van Esch JH, Sluiter W, et al. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension 2010; 56:675-681.
23. Kisanuki YY, Emoto N, Ohuchi T, et al. Low blood pressure in endothelial cellspecific endothelin 1 knockout mice. Hypertension 2010; 56:121-128.
24. Rautureau Y, Coelho SC, Fraulob-Aquino JC, et al. Inducible human endothelin-1 overexpression in endothelium raises blood pressure via ETA receptors. Hypertension 2015; 66:347-355.
25. Lee KJ, Kim MK, Park YH, et al. Vascular endothelial growth factor induces endothelin-1 production via matrix metalloproteinase-2 rather than endothelinconverting enzyme-1. Hypertens Pregnancy 2007; 26:189-199.
26. Seol HJ, Oh MJ, Kim HJ. Endothelin-1 expression by vascular endothelial growth factor in human umbilical vein endothelial cells and aortic smooth muscle cells. Hypertens Pregnancy 2011; 30:295-301.
27. Star GP, Giovinazzo M, Lamoureux E, et al. Effects of vascular endothelial growth factor on endothelin-1 production by human lung microvascular endothelial cells in vitro. Life Sci 2014; 118:191-194.
28. LaMarca B, Wallace K, Herse F, et al. Hypertension in response to placental ischemia during pregnancy: role of B lymphocytes. Hypertension 2011; 57:865-871.
29. Lee S, Chen TT, Barber CL, et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007; 130:691-703.
30. Alexander BT, Rinewalt AN, Cockrell KL, et al. Endothelin type a receptor blockade attenuates the hypertension in response to chronic reductions in uterine perfusion pressure. Hypertension 2001; 37:485-489.
31. Tam Tam KB, George E, Cockrell K, et al. Endothelin type A receptor antagonist attenuates placental ischemia-induced hypertension and uterine vascular resistance. Am J Obstet Gynecol 2011; 204:330.
32. Lankhorst S, Kappers MH, van Esch JH, et al. Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study. Hypertension 2014; 64:1282-1289.
33. Kappers MH, de Beer VJ, Zhou Z, et al. Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress. Hypertension 2012; 59:151-157.
34. Liu C, Chen J, Gao Y, et al. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev 2013; 2:4434.
35. Oudiz RJ, Galie N, Olschewski H, et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54:1971-1981.
36. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369:809-818.
37. Arefiev K, Fiorentino DF, Chung L. Endothelin receptor antagonists for the treatment of Raynaud's phenomenon and digital ulcers in systemic sclerosis. Int J Rheumatol 2011; 20:87-94.
38. Rosano L, Spinella F, Bagnato A. Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2013; 13:637-651.
39. Cross DM, Horsley E, Derzi M, et al. An evaluation of reproductive and developmental toxicity of sitaxentan (thelin) in rats. Birth Defects Res B Dev Reprod Toxicol 2012; 95:327-336.
40. Thaete LG, Khan S, Synowiec S, et al. Endothelin receptor antagonist has limited access to the fetal compartment during chronic maternal administration late in pregnancy. Life Sci 2012; 91:583-586.
41. Streit M, Speich R, Fischler M, et al. Successful pregnancy in pulmonary arterial hypertension associated with systemic lupus erythematosus: a case report. J Med Case Rep 2009; 3:7255.
42. Pruthi D, Khankin EV, Blanton RM, et al. Exposure to experimental preeclampsia in mice enhances the vascular response to future injury. Hypertension 2015; 65:863-870.